Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(8%)
Results Posted
67%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_4
2
17%
Ph phase_2
1
8%
Ph not_applicable
6
50%
Ph phase_3
1
8%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
6(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(5)

Detailed Status

unknown5
Completed3
Terminated2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 42 (20.0%)
N/A6 (60.0%)

Trials by Status

unknown542%
not_yet_recruiting18%
recruiting18%
completed325%
terminated217%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
OTHER
Total Trials
12